Reading EXEL? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track EXEL free→Reading EXEL? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track EXEL free→NASDAQHealth CareBiotechnologySnapshot 2026-06-12
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, but earnings quality and management's track record are neutral. The sector backdrop is a headwind, although EXEL is performing above typical compared to sector peers. Peer multiples imply a price about 7% above where it trades (it looks cheap on this basis); the read is fair. Key factors to watch include any potential guidance cuts and the performance of sector bellwethers like VRTX and REGN. This analysis is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 7 valuation methods, at three horizons. Current price $53.13. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $53 EXEL trades at 16× p/e, below its 16× p/e peer median. Our $57 fair value sits above the price; high confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 7% below a flat-multiple fair value, in line with our forecast of about 2%. This describes what's priced in, not a forecast of the move.
Only weak execution quality, a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 1.11x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 50% for the rest of the cohort, n=2269).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.86 → $0.86 (+0.0% / 30d). 9 raised, 1 cut, 9 covering analysts.
0 upgrades, 0 downgrades / 30d. 50% of analysts rate Buy.
0 positive, 0 negative / 30d.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$112.
How much price usually moves either way.
On a bad day, this stock has moved -$304.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $2,516.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
Company momentum fell by 13.9 points (from 51.3 to 37.4).
As of June 12, 2026, company momentum fell. This indicates a decrease in recent performance. The sector backdrop remains a headwind, suggesting challenges in the overall environment for the sector. The risk level is moderate, reflecting the current market conditions.
as of 2026-06-12
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Progress on the buyback program could signal management's confidence in the stock's value.
Confirms:Management says they have bought back a large part of the $750 million.
Disproves:No updates or delays in the buyback program are reported.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
Advances: Revenue growth
Growing sales support revenue growth objective.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On May 5, 2026, Exelixis, Inc. (Exelixis) issued a press release announcing its financial results for the quarter ended April 3, 2026, and providing a corporate update. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this report, including the exhibit hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or o…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Roughly priced in line with peers.
Cheaper than its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
EXEL Exelixis | Above typical Show detailsSector percentile: 99 of 100 | fair | moderate |
ABBV AbbVie | Above typical Show detailsSector percentile: 79 of 100 | full | low |
AMGN Amgen | Above typical Show detailsSector percentile: 75 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 96 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 82 of 100 | expensive | moderate |
2 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
Not investment advice. As of 2026-06-12.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-12.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Exelixis announced a new stock repurchase program of up to $750 million by December 31, 2027.
Exelixis aims to maintain revenue growth with a guidance range of $2.525 billion to $2.625 billion for fiscal year 2026.
Exelixis aims to increase operating income, with a focus on maintaining profitability.
Why it matters: A drop in sector growth could affect Exelixis' performance and how investors feel.
Confirms:Sector revenue growth reported below 10% year over year.
Disproves:Sector revenue growth remains above 10% year over year.
Why it matters: High operating income shows good financial health and growth.
Confirms:Operating income was over $250 million for Q2 2026.
Disproves:Operating income falls below $200 million for Q2 2026.
Why it matters: Steady revenue growth keeps investors confident. It also helps the company stay valuable.
Confirms:Quarterly revenue growth reported above 10% year over year.
Disproves:Quarterly revenue growth falls below 5% year over year.
Other Events. Stock Repurchase On May 5, 2026, Exelixis announced that the Board of Directors authorized the repurchase of up to an additional $750 million of its common stock by December 31, 2027. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference only with respect to the discussion in the section titled “October 2025 Stock Repurchase Program (SRP) Update and Announcement of New $750 million SRP Authorized in May 2026.”
The filing pertains to the amendment and restatement of an equity incentive plan, not a management change.